While Talaris Therapeutics is ending two clinical tests of its cell therapy in kidney transplant patients, a third study in the autoimmune condition scleroderma is continuing. Meanwhile, the biotech’s restructuring plan is pursuing “strategic alternatives” that could include a merger or sale.
Three biotechs IPOs priced this week while one gene therapy developer postponed its plans. The biggest IPO belongs to Talaris Therapeutics, a company developing a cell therapy for organ transplant patients that could mean the end of lifelong immunosuppressive drugs that prevent rejection.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Molina will acquire Passport Health Plan’s Medicaid and dual-eligible business for $20 million. The Kentucky-based company is a long-standing provider of Medicaid managed care plans, but lost a bid with the state earlier this year.
Humana alleges that Mallinckrodt illegally jacked up the price of the injected drug Acthar, causing the insurance company to pay several times more for the drug - which the FDA approved in 1952 - than it otherwise would have.
The deal leaves Bain Capital with a minority stake in the company and values Waystar at $2.7 billion.
The so-called Destination: Health network will launch later this year with Aetna Medicaid members in Louisville, Kentucky and Aetna dual-eligible special needs plan members in Tampa, Florida and Southeastern Louisiana.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Earlier this year, Bloomberg News reported that Bain Capital was considering a sale of Waystar with Oracle and Visa named as two potential acquirers.
The insurer said it will provide compensation for better care navigation based on quality and cost metrics across various parts of the patient journey ranging from inpatient admissions, ED visits, prescription drugs, diagnostics and radiology.
Under the terms of the deal, select Humana Medicare Advantage HMO plan and dual-eligible members in Southern and Central California will have in-network access to Heritage Provider Network's facilities and physician practices.
The startups in the accelerator's fall 2018 cohort, which will go through a 13-week program, are bringing their expertise to a plethora of areas in healthcare, including education, nursing homes, athletics and NICUs.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
In a recent phone interview, Humana CMO Dr. Roy Beveridge chatted about value-based care, social determinants of health, 2018 predictions and what the Louisville, Kentucky-based payer has been up to.
A new study from Doximity, a physician social network, found a significant language gap between physicians and patients is prevalent in cities such as Washington, D.C., Minneapolis and Boston.
The acquisition is intended to diversify the vendor's analytics tools as both companies focus on providing tools to support value-based care.
Helping payers compensate providers on the basis of high-value care metrics will also be a growing area of focus, said RowdMap Cofounder and CSO Joshua Rosenthal.
We're not six months into 2017 yet. But already, a number of healthcare leaders have turned in their resignation letters due to significant problems at their organizations.